RNV

RENERVE FPO [RNV]
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Healthcare · ASX Small Cap
$0.0800 +0.0%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when RNV triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track RNV — Free

Active Signals

Bullish Signals

  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Volume surging at 355.9x normal while price falls — heavy selling pressure
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Low cash runway (4 quarters) - dilution risk
  • Strong revenue growth (+60%)
  • Near 52-week low (7% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • CANSLIM S: Tight float (49%)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +60% — the top line is moving in the right direction
  • Liquidity risk: 9 zero-volume days in last 20
  • Beneish M-Score 4.88 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 10d (+5pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.49%/day)
Ask Scout AI about RNV
"What's driving RNV today?" "How does RNV compare to peers?" "Key risks for RNV?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notification regarding unquoted securities - RNV
NONE Proposed issue of securities - RNV
NONE ReNerve Secures up to A$5 Million Funding Facility
Announcement tone +3pts

Recent ASX Announcements

2026-07-13 Notification regarding unquoted securities - RNV
2026-07-08 Proposed issue of securities - RNV
2026-07-08 ReNerve Secures up to A$5 Million Funding Facility PRICE SENSITIVE
2026-07-06 ReNerve Secures Marketing Approval in Indonesia PRICE SENSITIVE
2026-06-15 Notification of cessation of securities - RNV

Key Metrics

$13.8M
Market Cap
47K
Avg Volume
355.9x
Vol Ratio
$0.07 — $0.22
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-74.9%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 49%
LLeader vs LaggardlaggardRS: -7
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:RNV vs ECSRNV vs VHLRNV vs NTI
Scout Pro — Deeper Analysis for RNV
Try Pro free for 30 days
Share this analysis

Track RNV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required